Compare MUC & NBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MUC | NBTX |
|---|---|---|
| Founded | N/A | 2003 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.0B |
| IPO Year | 1997 | 2018 |
| Metric | MUC | NBTX |
|---|---|---|
| Price | $10.72 | $32.06 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $26.00 |
| AVG Volume (30 Days) | ★ 243.5K | 42.4K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $11.73 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.97 | $2.99 |
| 52 Week High | $11.04 | $41.89 |
| Indicator | MUC | NBTX |
|---|---|---|
| Relative Strength Index (RSI) | 38.37 | 55.28 |
| Support Level | $10.71 | $20.11 |
| Resistance Level | $10.78 | $41.89 |
| Average True Range (ATR) | 0.09 | 2.83 |
| MACD | -0.02 | -0.37 |
| Stochastic Oscillator | 8.57 | 32.97 |
BlackRock MuniHoldings California Quality Fund Inc is a diversified, closed-end management investment company. Its investment objective is to provide shareholders with current income exempt from U.S. federal income taxes and California personal income taxes. The fund mainly invests in municipal obligations exempt from U.S. federal income taxes (except that the interest may be subject to the U.S. federal alternative minimum tax) and California personal income taxes. Under normal market conditions, it invests a majority of its managed assets in investment-grade municipal obligations with remaining maturities of one year or more at the time of investment. It can also invest in below investment-grade securities, or directly in such securities or synthetically through the use of derivatives.
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.